Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mosseri Marlio Charles is named as a reporting person in SEC Form 4 filings. OQRO lists 13 transactions filed with the SEC under this name, the latest on Jun 24, 2025, each linked to the official Form 4.
Disclosures on record
13
Companies involved
1
As of the latest filing on , Mosseri Marlio Charles reported holding 5,625,927 shares of Nuvectis Pharma (NVCT), worth about $109M at the last close of $19 (Nov 20, 2026): 2,644,121 held directly and 2,981,806 through an emerald hill ventures sarl spf.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Nuvectis Pharma NVCT | 5,625,927 | 2.64M direct · 2.98M emerald hill ventures sarl spf | $19 | $109M | Jun 20, 2025 |
Is this Mosseri Marlio Charles’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
6 buys, median −31.0 pts vs S&P 500, beat it 2 of 6 times.
Average −2.6 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Dec 16, 2024 to Jun 24, 2025, measured from the first close after the filing. Past results, not a forecast.
6 purchases disclosed; 33% of the 6 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Nuvectis PharmaNVCT
13 disclosures · Dec 2024 – Jun 2025 · 13 bought
Jun 20, 2025Bought~$45Kdisclosed Jun 24
DetailsOfficial recordJun 18, 2025Bought~$226Kdisclosed Jun 20
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Jun 17, 2025Bought~$44Kdisclosed Jun 20
DetailsOfficial recordMay 12, 2025Bought~$172Kdisclosed May 13
DetailsOfficial recordMay 9, 2025Bought~$87Kdisclosed May 12
DetailsOfficial recordMay 9, 2025Bought~$88Kdisclosed May 12
DetailsOfficial recordMay 9, 2025Bought~$48Kdisclosed May 12
DetailsOfficial recordMay 8, 2025Bought~$22Kdisclosed May 12
DetailsOfficial recordMay 8, 2025Bought~$871disclosed May 12
DetailsOfficial recordMay 8, 2025Bought~$899disclosed May 12
DetailsOfficial recordFeb 7, 2025Bought~$1.2Mdisclosed Feb 11
DetailsOfficial recordDec 12, 2024Bought~$149Kdisclosed Dec 16
DetailsOfficial recordDec 13, 2024Bought~$80Kdisclosed Dec 16
DetailsOfficial recordMosseri Marlio Charles bought shares on the open market in 2023, 2024 and 2025.
Mosseri Marlio Charles reported 33 open-market purchases and 0 sales since 2023; purchases in 3 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $1.93M11×11 trades | — |
| 2024 | $229K2×2 trades | — |
| 2023 | $3.57M20×20 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Jun 20, 2025, Mosseri Marlio Charles reported holding 5,625,927 shares of Nuvectis Pharma (NVCT), of which 2,981,806 are held indirectly. At the last close of $19 on Nov 20, 2026, that is about $109M. This is the stake disclosed in filings, not a net worth.
No public filing gives Mosseri Marlio Charles's net worth. What SEC Form 4 shows is the stock stake: 5,625,927 shares of Nuvectis Pharma (NVCT), about $109M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Mosseri Marlio Charles bought shares on the open market in 2023, 2024 and 2025.
In SEC filings since 2023: the latest open-market purchase is from 2025; no open-market sale is on record.
Nuvectis Pharma (NVCT), from 2023 to 2025: 33 purchases and 0 sales.
Mosseri Marlio Charles reported 33 open-market purchases and 0 sales here, 2023 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.